RE: International Patent Application No.: PCT/JP2014/002667
Your Ref: 50952-010WO1

(Translation)

(Amended) [Claim 1]

An inhibitor for formation or atrophy of a retinochoroidal scar in subretinal, intraretinal, or epiretinal tissue comprising (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof, or a salt thereof as an effective ingredient.

(Amended) [Claim 2]

The inhibitor for formation or atrophy of a retinochoroidal scar of claim 1, wherein the (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, the ester thereof, or the salt thereof is (E)-4-(2-{3-[(1H-pyrazole-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid or a salt thereof.

(Cancelled) [Claim 3]

(Amended) [Claim 4]

The inhibitor for formation or atrophy of a retinochoroidal scar of claim 1 or 2, wherein a form of administration is instillative administration or oral administration.

(Amended) [Claim 5]

The inhibitor for formation or atrophy of a retinochoroidal scar accordingly to any one of claims 1, 2, or 4, wherein a dosage form is an instillation, an ophthalmic ointment, an injection, a tablet, a granule, a fine granule, a powder or a capsule.

*Support for the amendments

(1) Claim 1 on page 15 in the Claims is amended as recited in the attached sheet. The content of the amendments is based on the matters described in paragraph [0009] in the specification

as of the filing and claim 3 in the Claims as of the filing.
(2) Claim 2 on page 15 in the Claims is amended as recited in the attached sheet. The content of the amendments is based on the matters described in paragraph [0009] in the specification as of the filing and claim 3 in the Claims as of the filing.
(3) Claim 3 on page 15 in the Claims is cancelled.
(4) Claim 4 on page 15 in the Claims is amended as recited in the attached sheet. The content of the amendments is based on the matters described in paragraph [0009] in the specification as of the filing and claim 3 in the Claims as of the filing.
(5) Claim 5 on page 15 in the Claims is amended as recited in the attached sheet. The content of the amendments is based on the matters described in paragraph [0009] in the specification as of the filing and claim 3 in the Claims as of the filing.